-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Haemonetics, Lowers Price Target to $70

Benzinga·08/08/2025 12:10:09
Listen to the news
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the price target from $90 to $70.